Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Autor:	Guzik, Katarzyna, Tomala, Marcin, Muszak, Damian, Konieczny, Magdalena, Hec, Aleksandra, Błaszkiewicz, Urszula, Pustuła, Marcin, Butera, Roberto, Dömling, Alexander, Holak, Tad A., Kafarski, Pawel
Předmět:	SMALL molecules PEPTIDES MONOCLONAL antibodies PROGRAMMED cell death 1 receptors DRUG design CANCER treatment MACROCYCLIC compounds
Zdroj:	Molecules; Jun2019, Vol. 24 Issue 11, p2071-2071, 1p, 5 Color Photographs, 28 Diagrams, 4 Graphs
Abstrakt:	Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such as high production cost of the antibodies or their long half-life. Small-molecule inhibitors of the PD-1/PD-L1 interaction have been highly anticipated as a promising alternative or complementary therapeutic to the monoclonal antibodies (mAbs). Currently, the field of developing anti-PD-1/PD-L1 small-molecule inhibitors is intensively explored. In this paper, we review anti-PD-1/PD-L1 small-molecule and peptide-based inhibitors and discuss recent structural and preclinical/clinical aspects of their development. Discovery of the therapeutics based on small-molecule inhibitors of the PD-1/PD-L1 interaction represents a promising but challenging perspective in cancer treatment. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.